Maria H. Ribeiro

Pharmaceutical Bioengineering, Biotechnology & Bioproducts

PharmaBB aims at developing innovative research, exploring bioengineering & biotechnology, to disease prevention, health promotion and well-being. Our Group brings together different areas of expertise, contributing to achieve a higher knowledge based on the manufacturing of bioactive compounds using green technologies, biofabrication of (bio)materials and gene/drug delivery platforms towards (bio)therapeutics (against infectious, cancer or neuroprotection), medical devices, biomedical and food applications.

Within the framework of iMed, the main scientific ongoing and future research interests of PharmaBB Group, amultidisciplinary team with expertise on biological and physicochemical processes, are the promotion of translational research in the pharmaceutical and biomedical field within the scope of Emerging Technologies area, addressing diseases as infectious and cancer, or neuroprotectors, delivery and transfection agents, with efficacy, safety, ability and availability to and at the target site.

Our focus addresses the challenges associated with emerging technologies related to:

– Develop sustainable cell and enzyme-based platforms: from bioengineering, biocatalysts improvement (e.g. immobilization, high pressure), bioprocess intensification through bioreactor miniaturization to downstream processing;

– Design and implementation of innovative bioconversions towards value-added bioactive compounds (e.g. anticancer, antimicrobial, anti-inflammatory, neuroprotector) with pharmaceutical and food applications towards disease prevention and health promotion;

– Develop LC-MS/MS tools and other analytical methods to characterize and identify synthesised bioproducts with pharmaceutical/ therapeutic relevance and to determine levels of contaminants and additives in scale-up developed drugs, biological and food samples;

– Design and develop tools and tailoring, functionalization and biocompatibility studies of biomaterials and medical devices antimicrobial properties and prevent infection

Develop and characterization of gene/drug delivery platforms for biotechnology-derived therapeutics complement the competencies of the Group.

The beneficial health effects of the bioactive molecules and biomaterials are studied using in vitro (cell models) and in vivo tools of disorders, as inflammatory, cancer, age-related, in collaboration with other groups of iMed.

Bettencourt AB, Tomé C, Oliveira T, Martin V, Santos C, Gonçalves L, Fernandes MH, Gomes PS, Ribeiro IAC. Exploring the potential of chitosan-based particles as delivery-carriers for promising antimicrobial glycolipid biosurfactants. Carbohydr Polym 2021; 254: 117433. DOI: 10.1016/j.carbpol.2020.117433
Carvalho PM, Guedes RC, Bronze MR, Faustino CMC, Ribeiro MHL. Design of a new gemini lipoaminoacid with immobilized lipases based on an eco-friendly biosynthetic process. Catalysts 2021; 11: 164. DOI: 10.3390/catal11020164
Faustino CMC, Lemos SMC, Monge N, Ribeiro IAC. A scope at antifouling strategies to prevent catheter-associated infections. Adv Colloid Interface Sci 2020; 284: 102230. DOI: 10.1016/j.cis.2020.102230
Guerfali M, Ayadi I, Mohamed N, Ayadi W, Belghith H, Bronze MR, Ribeiro MHL, Gargouri A. Triacylglycerols accumulation and glycolipids secretion by the oleaginous yeast Rhodotorula babjevae Y-SL7: Structural identification and biotechnological applications. Bioresource Technol 2019; 273: 326-334. DOI: 10.1016/j.biortech.2018.11.036
Martins S, Albuquerque BA, Nunes M, Ribeiro MHL. Exploring magnetic and imprinted cross-linked enzyme aggregates of rhamnopyranosidase in microbioreactors. Bioresource Technol 2018; 249: 704-712. DOI: 10.1016/j.biortech.2017.10.078

Maria H. Ribeiro

Group Leader


Phone: (+351) 217946400 (Ext. 14331)

View Profile
Back To Top
Come meet us at

Faculdade de Farmácia da Universidade de Lisboa | Av. Professor Gama Pinto
1649-003 Lisboa | Portugal

Phone | +351 217 946 400
Fax | +351 217 946 470
Web |
Email |